Business Context and Reporting Period
Beyond Air, Inc. (XAIR) is a commercial-stage medical device and biopharmaceutical company developing the LungFit® platform, which generates nitric oxide (NO) from ambient air. The company's primary approved product, LungFit® PH, received FDA PMA approval in June 2022 for treating persistent pulmonary hypertension of the newborn (PPHN) and received European CE mark approval in November 2024. The company also operates two majority-owned subsidiaries: Beyond Cancer (80% owned), focusing on ultra-high concentration NO for solid tumors, and NeuroNOS (88.2% owned), focusing on nNOS inhibitors for neurological conditions like autism spectrum disorder.
Reporting Period: Fiscal year ended March 31, 2025.
Key Financial Metrics
| Metric | Fiscal 2025 | Fiscal 2024 |
|---|---|---|
| Revenue | $3.7 million | $1.2 million |
| Cost of Revenues | $5.4 million | $2.5 million |
| Gross Loss | $(1.7) million | $(1.3) million |
| Net Loss (Total) | $(48.5) million | $(64.3) million |
| Net Loss (Attributable to Beyond Air) | $(46.6) million | $(60.2) million |
| Operating Cash Flow | $(38.2) million | $(56.0) million |
| Cash & Marketable Securities | $6.9 million | $34.5 million |
| Long-Term Debt (Net) | $9.2 million | $14.7 million |
| Accumulated Deficit | $(286.3) million | $(239.7) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 219% to $3.7 million, driven by additional hospital contracts in the U.S. market. However, cost of revenue grew faster than revenue, resulting in a gross loss of $1.7 million due to supply chain infrastructure costs and depreciation of new devices.
- Expense Reduction: Total operating expenses decreased 30% to $42.9 million. Research and Development (R&D) expenses dropped 31% to $16.9 million, and Selling, General, and Administrative (SG&A) expenses fell 30% to $26.0 million. These reductions were primarily due to decreased stock-based compensation ($12.2 million reduction) and lower salary expenses following a capital conservation strategy that reduced staffing by over 30%.
- Debt Restructuring: The company extinguished a $17.5 million senior secured term loan with Avenue Capital in September 2024 for a one-time payment of $17.85 million, recording a $2.4 million loss on extinguishment. Concurrently, the company entered a new $11.5 million secured loan agreement in November 2024 with related parties (CEO and Director) at 15% interest (3% cash, 12% PIK).
- Equity Financing: The company raised approximately $20.6 million in gross proceeds via a private placement in September 2024 (Securities Purchase Agreement II), issuing common stock, pre-funded warrants, and common warrants.
Guidance, Outlook, and Risks
- Going Concern: The independent auditors have expressed substantial doubt about the company's ability to continue as a going concern. Management expects to incur net losses and significant cash outflows for at least the next 12 months and requires additional funding to meet obligations.
- Capital Conservation: The company has implemented a capital conservation strategy, including placing the Viral Community-Acquired Pneumonia (VCAP) clinical study on hold pending future funding and adjusting production forecasts.
- Commercial Outlook: The company expects significant revenue contributions in fiscal 2026 and beyond from new distribution agreements in Europe, Asia, and the Middle East, as well as partnerships with TrillaMed and Healthcare Links.
- Nasdaq Compliance: The company is currently non-compliant with Nasdaq's $1.00 minimum bid price requirement. It has been granted an additional 180-day compliance period until August 4, 2025. Failure to regain compliance could result in delisting.
- Key Risks: Risks include the need for additional capital, dependence on third-party manufacturers (87% of materials from one vendor), regulatory hurdles for product candidates, and intense competition in the NO delivery market.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $6.9 million cash balance against the $38.2 million annual operating cash burn and the terms of the new $11.5 million loan.
- Nasdaq Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement by August 4, 2025, to avoid delisting.
- Debt Covenants: Review the covenants of the November 2024 Loan Agreement, specifically the 15% interest rate (12% PIK) and the 8% royalty on net sales starting July 2026.
- Revenue Quality: Assess the sustainability of revenue growth given the high cost of revenue and the concentration of revenue from a few customers (16% and 10% from two customers in FY2025).
- Clinical Pipeline Funding: Confirm the status of the paused VCAP study and the funding requirements for the Beyond Cancer Phase 1b and NeuroNOS Phase 1 trials.